Facebook
Twitter
LinkedIn
Forward
We are at a unique place in obesity care history where anti-obesity medications (AOMs) are showing promising, clinically significant weight loss for persons with obesity.
|
This session with review the relationship and underlying mechanisms between obesity and cardiovascular disease with attention to the individual variability between BMI and CV risk.
|
Weight stigma is an often-overlooked contributor to poor patient engagement and weight gain over time.
|
This presentation will provide an overview of the evidence basis for using continuous glucose monitoring (CGM) in patients with obesity.
|
This session will focus on the management of non-alcoholic fatty liver disease (NAFLD) with a particular emphasis on the role of GLP-1 agonists and SGLT-2 inhibitors in treating this condition.
|
In this session, Liz Paul will describe her experiences living with obesity, including her journey to overcoming internalized weight bias.
|
Obesity is a disease that disproportionately affects women. Those from ethnic/racial minorities and those who live in poverty are often more severely affected.
|
OMA Clinical Practice Statement Updates - Harold Bays, MD, FOMA, Lydia Alexander, MD, FOMA, Karlijn Burridge, PA-C, Suzanne Cuda, MDCME/CE Expiration Date: 3/19/25
|
Over the last decade, the FDA has approved five new medications for the treatment of obesity. The latest edition, semaglutide, published impressive weight loss results and we are just beginning.
|
Discussing obesity with patients can be challenging. Motivational interviewing (MI) is and effective way to initiate, sustain, and move forward with obesity treatment.
|